Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin
International Journal of Molecular Sciences · 14.12.2024 · 25 (24) · 13416
DOI: 10.3390/ijms252413416 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.12.2024. Verfasst von Paola Poma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Chemical and Pharmaceutical Science and Technology (STEBICEF), University of Palermo, 90128 Palermo, Italy. Hauptthemen laut MEDLINE: Curcumin, Doxorubicin, Epigenesis, Genetic, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finanziamento di progetti di ricerca interdisciplinari, di progetti di ricerca interdisciplinari.
Abstract (Originalsprache)
The MCF-7R breast cancer cell line, developed by treating the parental MCF-7 cells with increasing doses of doxorubicin, serves as a model for studying acquired multidrug resistance (MDR). MDR is a major challenge in cancer therapy, often driven by overexpression of the efflux pump P-glycoprotein (P-gp) and epigenetic modifications. While many P-gp inhibitors show promise in vitro, their nonspecific effects on the efflux pump limit in vivo application. Curcumin, a natural compound with pleiotropic action, is a nontoxic P-gp inhibitor capable of modulating multiple pathways. To explore curcumin’s molecular effects on MCF-7R cells, we analyzed the expression of genes involved in DNA methylation and transcription regulation, including ABCB1/MDR1. Reduced representation bisulfite sequencing further unveiled key epigenetic changes induced by curcumin. Our findings indicate that curcumin treatment not only modulates critical cellular processes, such as ribosome biogenesis and cytoskeletal dynamics, but also reverses the resistant phenotype, toward that of sensitive cells. This study highlights curcumin’s potential as an adjuvant therapy to overcome chemoresistance, offering new avenues for pharmacological strategies targeting epigenetic regulation to re-sensitize resistant cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Chemical and Pharmaceutical Science and Technology (STEBICEF), University of Palermo, 90128 Palermo, Italy.
- Institute for Biomedical Research and Innovation-National Research Council (IRIB-CNR), 90146 Palermo, Italy.
ORCID-Profile: Salvatrice Rigogliuso, Aldo Nicosia, Salvatore Costa, Maria Antonietta Ragusa
Förderung
- Finanziamento di progetti di ricerca interdisciplinari
- di progetti di ricerca interdisciplinari
Zitieren
APA
Poma, P., Rigogliuso, S., Labbozzetta, M., Nicosia, A., Costa, S., Ragusa, M. A., & Notarbartolo, M. (2024). Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin. International Journal of Molecular Sciences, 25(24), 13416. https://doi.org/10.3390/ijms252413416
Vancouver
Poma P, Rigogliuso S, Labbozzetta M, Nicosia A, Costa S, Ragusa MA, et al. Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin. International Journal of Molecular Sciences. 2024;25(24):13416. doi:10.3390/ijms252413416
BibTeX
@article{Poma2024,
author = {Poma, Paola and Rigogliuso, Salvatrice and Labbozzetta, Manuela and Nicosia, Aldo and Costa, Salvatore and Ragusa, Maria Antonietta and Notarbartolo, Monica},
title = {Epigenetic and Cellular Reprogramming of Doxorubicin-Resistant MCF-7 Cells Treated with Curcumin},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {24},
pages = {13416},
doi = {10.3390/ijms252413416}
}
EUVIMED